Definium Therapeutics (DFTX) Resumen de Acciones
Definium Therapeutics, Inc. es una empresa biofarmacéutica que desarrolla nuevos productos candidatos para tratar trastornos cerebrales. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 4/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
DFTX Community Fair Values
Create NarrativeSee what 68 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Definium Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$44.19 |
| Máximo en las últimas 52 semanas | US$49.20 |
| Mínimo de 52 semanas | US$6.95 |
| Beta | 2.21 |
| Cambio en 1 mes | 87.64% |
| Variación en 3 meses | 116.30% |
| Cambio de 1 año | 516.32% |
| Variación en 3 años | 1,081.55% |
| Variación en 5 años | -16.31% |
| Variación desde la OPV | 407.41% |
Noticias y actualizaciones recientes
Recent updates
DFTX: Phase 3 Depression Data Will Likely Prove Priced In
Definium Therapeutics' updated fair value estimate has moved from $20.00 to about $35.66 as analysts raise price targets into the $57 to $74 range, citing strong Phase III EMERGE data for DT120 in major depressive disorder and increased confidence in the program across additional indications. Analyst Commentary Recent Street research on Definium Therapeutics centers on the Phase III EMERGE data for DT120 in major depressive disorder, with multiple firms updating their models and adjusting price targets to reflect the reported effect size, durability of response, and safety profile.Definium: Phase 3 MDD Data Wins Over Wall Street, But Caution Still Advised
Summary Definium Therapeutics surged ~50% after positive Phase 3 EMERGE data for DT120 in major depressive disorder, demonstrating rapid, robust, and durable efficacy. DTFX's DT120 showed a -8.1 point MADRS score improvement over placebo at week 6, with promising safety and single-dose administration in a controlled setting. Despite $373.4m cash and a $500m raise, DTFX's $4bn pre-commercial valuation appears high given remaining regulatory, commercial, and competitive uncertainties. I maintain a Hold rating, preferring to await upcoming Phase 3 GAD and ASCEND MDD data to clarify DT120’s risk/reward profile before considering a more bullish stance. Read the full article on Seeking Alpha
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Summary Initiating coverage on Mind Medicine with a Hold rating due to regulatory uncertainties around rescheduling Schedule I compounds for medical use. Despite strong cash resources and promising Phase 3 trials, regulatory delays could hinder MNMD's patient access and market entry. The global GAD, MDD, and ASD markets present significant growth opportunities, but MM120 faces competition and unique safety and scheduling issues. Positive Phase 3 outcomes could drive regulatory progress, but until FDA and DEA clear rescheduling, broad patient access and reimbursement remain uncertain. Read the full article on Seeking AlphaMindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Summary Mind Medicine (MindMed) Inc.'s stock has surged over 160% since my October 2022 “Hold” call, driven by positive Phase 2b data for MM120 in treating GAD. Despite financial stability and promising Phase 3 trials, significant hurdles remain, including DEA rescheduling of LSD and FDA approval challenges. The company faces issues with patenting naturally occurring substances and potential reluctance from insurers and physicians to adopt psychedelic therapies. While MindMed shows progress, I remain cautious due to regulatory and commercial obstacles, maintaining my “Hold” rating on MNMD amidst ongoing uncertainties. Read the full article on Seeking AlphaMind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Summary Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. Investors should watch for key milestones in 2026 and consider risks related to trial outcomes and regulatory approval for MM-120 and MM-402. Read the full article on Seeking AlphaPsychedelic Stocks: Focus On Their Cash
Summary Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. Major players in the psychedelic medicine space are well-funded, moving into Phase 3 trials, with potential for significant milestones in the near future. Read the full article on Seeking AlphaMindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033. MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA. Read the full article on Seeking AlphaMind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Summary Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Read the full article on Seeking AlphaMind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts
Summary Primary endpoint met of HAM-A scores at week 4 met in phase 2b MMED008 study, when Generalized Anxiety Disorder patients were given MM-120. 12-week HAM-A results from phase 2b MMED008 study in GAD to be released end of Q1 of 2024 with full data set at upcoming medical meeting in 2024. End of phase 2 meeting with FDA to discuss advancement of MM-120 for GAD expected in the 1st half of 2024; Phase 3 trial initiation expected 2nd half of 2024. The generalized anxiety disorder market size is estimated to reach $8.1 billion by 2027. Read the full article on Seeking AlphaRentabilidad de los accionistas
| DFTX | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -1.7% | 1.4% | 1.6% |
| 1Y | 516.3% | 48.6% | 18.6% |
Rentabilidad vs. Industria: DFTX superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 48.6% el año pasado.
Rentabilidad vs. Mercado: DFTX superó al mercado US, que obtuvo un rendimiento del 18.6% el año pasado.
Volatilidad de los precios
| DFTX volatility | |
|---|---|
| DFTX Average Weekly Movement | 16.3% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de DFTX ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DFTX(16%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 106 | Rob Barrow | definiumtx.com |
Definium Therapeutics, Inc. es una empresa biofarmacéutica que desarrolla nuevos productos candidatos para el tratamiento de trastornos cerebrales. Los principales productos candidatos de la empresa son DT120, en fase 3 para el tratamiento del trastorno de ansiedad generalizada, el trastorno depresivo mayor y otros trastornos cerebrales, y DT402, un enantiómero R de 3,4-metilendioximetanfetamina, en fase 2a de ensayos clínicos para el tratamiento del trastorno del espectro autista. La empresa era conocida anteriormente como Mind Medicine (MindMed) Inc. y cambió su nombre por Definium Therapeutics, Inc. en enero de 2026.
Resumen de fundamentos de Definium Therapeutics, Inc.
| Estadísticas fundamentales de DFTX | |
|---|---|
| Capitalización bursátil | US$5.87b |
| Beneficios(TTM) | -US$237.54m |
| Ingresos (TTM) | n/a |
¿Está DFTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DFTX | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$237.54m |
| Beneficios | -US$237.54m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.79 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 14.6% |
¿Cómo se ha desempeñado DFTX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 19:27 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Definium Therapeutics, Inc. está cubierta por 22 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |